Use of Vascular Endothelial Growth Factor (VEGF) Inhibitors

    Basic Details
    Date Posted
    Tuesday, June 19, 2012
    Medical Product
    sorafenib tosylate
    sunitinib malate
    vascular endothelial growth factor (VEGF) inhibitor

    Summary table assessment of the prevalence of vascular endothelial growth factor (VEGF) inhibitors by generic drug name (bevacizumab, sorafenib tosylate, sunitinib malate, and thalidomide) in the Mini-Sentinel Distributed Database. Results were generated using the Mini-Sentinel Distributed Query Tool and the Dispensing Summary Table. Summary tables are precompiled stratified counts. Queries were executed in July/August 2011. This report includes data from 15 Data Partners.

    This document is an Excel spreadsheet that includes multiple layers of data configured using pivot tables. If you do not have Excel, click here to obtain a free version of Microsoft’s Excel Viewer.

    If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to

    The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer.

    Additional Details
    FDA Center
    Time Period
    2007 - 2011
    Study Type
    Summary Table
    Assessment Type
    Exploratory Analyses
    Data Sources
    Mini-Sentinel Distributed Database (MSDD)